Cancer Family
Neck Neoplasm
CI-CAN-00000283Explore in graph →
Non-malignant634 active trials11 approved drugs67 evidence items
- NCIt
- C3260
Loading cancer entity…
Cancer Family
CI-CAN-00000283Explore in graph →
Clinical trials
2,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05350891 | Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC | unknown | Phase 2 | 77 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT03854838 | IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma. | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT04143984 | Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 146 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05341193 | PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT04508829 | Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy | unknown | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT04921995 | Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma(RETICULA-NPC) | unknown | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05299437 | Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry(131THEROPT124) | unknown | Phase 2 | 50 | Carlo ChiesaOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT04787328 | A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC) | unknown | Phase 2 | 30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 23, 2022 | clinicaltrials |
| NCT05232552 | Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 37 | Zhejiang Cancer HospitalOTHER | 1 | Feb 10, 2022 | clinicaltrials |
| NCT04952493 | Anlotinib or Penpulimab in Combination With RAI for DTC | unknown | Phase 2 | 42 | Peking Union Medical College HospitalOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT05198531 | To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer | unknown | Phase 1 / Phase 2 | 90 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 21, 2022 | clinicaltrials |
| NCT04995120 | Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma(INSIGHT) | unknown | Phase 2 | 42 | Fudan UniversityOTHER | 1 | Jan 18, 2022 | clinicaltrials |
| NCT05177237 | Endostar Combined With Corticosteroid for Treatment of Radiation-induced Brain Necrosis in Nasopharyngeal Carcinoma | unknown | Phase 2 | 30 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT05162872 | Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 99 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT02915432 | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC | unknown | Phase 1 / Phase 2 | 401 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT05092217 | Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 80 | Eye & ENT Hospital of Fudan UniversityOTHER | 0 | Oct 25, 2021 | clinicaltrials |
| NCT02041260 | A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting | unknown | Phase 2 | 43 | Thomas Jefferson UniversityOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT05020925 | SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 25, 2021 | clinicaltrials |
| NCT03668730 | Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 | 215 | Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04992988 | Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial | unknown | Phase 2 | 40 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT04539600 | Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer | unknown | Phase 2 | 23 | Sun Yat-sen UniversityOTHER | 1 | Aug 19, 2021 | clinicaltrials |
| NCT04955886 | Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 14 | Fujian Cancer HospitalOTHER_GOV | 1 | Jul 9, 2021 | clinicaltrials |
| NCT03904225 | Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis | unknown | Phase 2 | 220 | Zhejiang Cancer HospitalOTHER | 1 | Jun 23, 2021 | clinicaltrials |
| NCT04917770 | The Efficacy and Safety of Sintilimab in Combination With Multimodal Radiotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 28 | West China HospitalOTHER | 0 | Jun 8, 2021 | clinicaltrials |
| NCT04309136 | Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer | unknown | Phase 2 | 13 | Fudan UniversityOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04554680 | Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy | unknown | Phase 2 | 5 | National University Hospital, SingaporeOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT04769076 | The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma | unknown | Phase 2 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Feb 25, 2021 | clinicaltrials |
| NCT02636231 | Endostar for Locally Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 96 | Sun Yat-sen UniversityOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT03558035 | New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma | unknown | Phase 2 | 96 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03908372 | Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 120 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03915132 | Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 | 47 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT04627961 | A Trial of LONSURF in Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 33 | National University Hospital, SingaporeOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04624308 | Toripalimab Plus TPF Chemotherapy and Radiotherapy for LA-HPSCC | unknown | Phase 2 | 81 | Sun YanOTHER | 1 | Nov 10, 2020 | clinicaltrials |
| NCT04612894 | Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer | unknown | Phase 2 | 31 | Fudan UniversityOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT04574817 | Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC) | unknown | Phase 2 | 66 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT03129412 | Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions | unknown | Phase 2 | 64 | Zhejiang Cancer HospitalOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT04553510 | Treatment of Bevacizumab Followed by Steroid in RN | unknown | Phase 2 | 86 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 17, 2020 | clinicaltrials |
| NCT04547088 | Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 27 | Sun Yat-sen UniversityOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT04548271 | Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT04534855 | A Phase II Clinical Study of Treprilimab in the Treatment of Recurrent Nasopharyngeal Carcinoma After Re-irradiation | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 0 | Sep 1, 2020 | clinicaltrials |
| NCT04524884 | Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study | unknown | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT03648697 | EBV-TCR-T(YT-E001)for Patients With EBV-positive Recurrent or Metastatic NPC | unknown | Phase 2 | 20 | Fujian Cancer HospitalOTHER_GOV | 1 | Aug 11, 2020 | clinicaltrials |
| NCT04476641 | A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors(DC-CIK) | unknown | Phase 2 | 686 | Sun Yat-sen UniversityOTHER | 1 | Jul 20, 2020 | clinicaltrials |
| NCT04446663 | Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 50 | First People's Hospital of FoshanOTHER | 0 | Jun 25, 2020 | clinicaltrials |
| NCT04447326 | Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma | unknown | Phase 2 | 106 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 0 | Jun 25, 2020 | clinicaltrials |
| NCT04447612 | Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 118 | The University of Hong KongOTHER | 1 | Jun 25, 2020 | clinicaltrials |
| NCT04421469 | Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC | unknown | Phase 2 | 39 | Fujian Cancer HospitalOTHER_GOV | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04319471 | Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 70 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 24, 2020 | clinicaltrials |
| NCT04296747 | Toripalimab in Combination With Chemotherapy as Induced Chemotherapy for Localized Hypopharyngeal Cancer | unknown | Phase 2 | 100 | Peking Union Medical College HospitalOTHER | 0 | Mar 5, 2020 | clinicaltrials |
| NCT03923842 | Denosumab In Ebv Nasopharyngeal Carcinoma As A Model For RankMediated Immunologic Modulation Of Virus-Related Tumours(Dern) | unknown | Phase 2 | 45 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Feb 17, 2020 | clinicaltrials |
Data updated 23 days agoSource updated May 10, 2022source: clinicaltrials